Palliative Performance Scale (PPS)
Measures functional decline in palliative care patients across 5 domains. PPS <50% associated with median survival <3 months. Guides goals of care and support planning.
Score interpretation
→ Active treatment possible; goals: curative/life-prolonging; advance care planning introduction; support independence
→ Shift to comfort-focused goals; symptom management; palliative care team involvement; anticipatory prescribing; carer support
→ End-of-life care pathway; subcutaneous syringe driver; discontinue non-essential medications; anticipatory medications for pain, secretions, agitation; spiritual/emotional support; DNAR
Interpretation bands for the PPS Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Phenytoin / Fosphenytoin · Antiepileptic — Status Epilepticus (Second-Line)
- Levetiracetam (IV) · Antiepileptic — Status Epilepticus (Second-Line)
- Factor IX Concentrate · Coagulation Factor Replacement — Haemophilia B
- Levetiracetam IV (Status Epilepticus) · Antiepileptic — Second-Line Status Epilepticus
- Diazepam (Paediatric) · Benzodiazepine — Status Epilepticus / Febrile Convulsions (Community)
- Midazolam (Paediatric) · Benzodiazepine — Status Epilepticus (First-Line) / Procedural Sedation
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.